Whole-exome sequencing for finding de novo mutations in sporadic mental retardation
© BioMed Central Ltd 2010
Published: 21 December 2010
Skip to main content
© BioMed Central Ltd 2010
Published: 21 December 2010
Recent work has used a family-based approach and whole-exome sequencing to identify de novo mutations in sporadic cases of mental retardation.
Sarah Ng and colleagues first showed that whole-exome sequencing (WES - sequencing of all the exons in the genome) can be used to identify disease genes in 2009 . Clearly, WES represents a revolutionary technology. In light of the ever increasing number of novel disease genes that have been discovered with WES, it has almost come to seem routine, and in fact the first descriptions of applications of WES to make clinical decisions in the care of patients have begun to appear . The article by Lisenka Vissers and colleagues in the December 2010 issue of Nature Genetics  demonstrates that the revolution is far from over. By providing convincing evidence that WES can be used to detect de novo mutations in patients with sporadic cases of non-syndromic mental retardation, the authors  have extended the range of clinical situations in which WES can be used and given suggestive evidence that de novo mutations are a common cause of mental retardation.
One of the main challenges in WES is the sheer number of variants that are found in an exome. It is likely that each one of us - healthy or not - carries multiple sequence variants, such as nonsense mutations, that most geneticists would have assessed as disease-causing before whole-exome and whole-genome sequencing showed us how common such changes are in human genomes. The challenge in molecular genetic diagnostics is thus quickly shifting from the identification of sequence variants to the interpretation of the variants: which of the tens to hundreds of rare variants in an exome sequence with apparent pathogenic potential is the disease-causing mutation?
Initial analysis strategies in exome sequencing sought to identify genes with rare, potentially pathogenic variants in all or most sequenced individuals with a given disease [1, 4–6]. This approach, which we will call intersection filtering, narrows down the candidate set of genes by removing variants also found in databases of common polymorphisms such as dbSNP and also removing variants that are deemed to be unlikely to cause disease, such as synonymous or intergenic nucleotide substitutions. Several studies used linkage analysis in addition to WES to narrow down the region of the exome in which to search for candidate mutations. For autosomal recessive disorders, it is possible to infer linkage intervals directly from WES data in order to restrict the search space .
None of these analysis strategies is applicable to single cases of sporadic disease. The study of Vissers et al.  was motivated by recent estimations that put the per generation mutation rate at about 1 in 100 million positions in the haploid genome, which corresponds to 0.86 de novo amino acid altering mutations per newborn [8, 9]
The authors  developed an analysis strategy that involves a family-based WES approach in which case-parent trios are sequenced in order to identify potentially pathogenic de novo changes in the exome sequences of the affected children. De novo copy number variations (CNVs) are a known cause of mental retardation, so array comparative genome hybridization (CGH) investigations were used to rule out such CNVs before WES was performed. The exome sequences of the affected child and the healthy parent of ten trios were captured in solution, and approximately 3 Gb of mappable sequence data was generated for each individual, with about 90% of the exons of the about 18,000 targeted genes being covered at least 10 times. There were nearly 22,000 high-confidence variant calls per individual, which were analyzed using a bioinformatic pipeline to exclude variants such as intergenic or synonymous variants that were unlikely to be disease-causing mutations. The remaining changes were filtered against databases of common variants, which reduced the search space to an average of 143 variants per patient. These variants were then compared with the exome sequences of the parents to remove inherited variants, leaving between two and seven candidate de novo mutations per trio.
The de novo mutations were all identified in different genes. A de novo nonsense mutation was identified in a 2-year-old boy with mental retardation in RAB39B, a gene encoding a small GTPase; this mutation is a known cause of X linked mental retardation (also called MRX72; MIM ID 300271). Another de novo nonsense mutation was found in an 8-year-old girl with mental retardation in SYNGAP1 (encoding synaptic Ras GTPase activating protein 1), a known cause of autosomal dominant mental retardation (also called MRD5; MIM ID 612621). No de novo mutation could be validated in the 10-year-old boy of trio 10, but a maternally inherited non-synonymous variant in JARID1C (also known as KDM5C, or lysine (K)-specific demethylase 5C) was identified. Mutations in this gene are a well known cause of syndromic X-linked mental retardation (MIM ID 300534). In four other individuals, de novo mutations were found in four genes that seem to be highly likely candidates based on model organism studies and sequence conservation of the affected amino acid residues, but that had not been previously proven to be related to mental retardation in humans. Strictly speaking, the proof that mutations in these genes cause mental retardation in humans will have to await the identification of additional mutations in more patients.
The authors  identified several additional de novo variants in their patients that probably have nothing to do with the mental retardation. These changes were in genes with no obvious connection to mental functioning, occurred in less highly conserved residues, and in two cases were found in addition to other de novo mutations in one of the candidate mental retardation genes. Thus, it seemed unlikely that these mutations are related to the cases of mental retardation. This leads to the obvious conclusion that the mere finding of a de novo missense mutation by WES cannot be taken as proof that the change is causally related to the disease being investigated.
It has been notoriously difficult to provide an etiological diagnosis in cases of sporadic mental retardation. Although detection rates vary widely between different reports, in general it has been possible to identify the cause of mental retardation in less than half of patients even after an extensive analysis . Vissers et al.  identified the conclusive or probable cause of mental retardation in seven of the ten cases they examined. Their results suggest that de novo mutations are a major cause of mental retardation and that family-based WES is not only an excellent approach for diagnostics in sporadic mental retardation but also a method of choice for the discovery of novel disease genes in mental retardation. It is tempting to speculate that similar approaches might be fruitful for other classes of sporadic disease with an apparent genetic background. The work of Vissels et al.  provides yet another demonstration of the enormous potential that the revolutionary method of WES has to improve diagnostic routines in genetics clinics and beyond.
The author's laboratory is supported by grants from the Deutsche Forschungsgemeinschaft (DFG SFB 760 and RO 2005/4-1), the Bundesministerium für Bildung und Forschung (BMBF, project number 0313911), and the European Commission (FAD; HEALTH-F2-2008-200647).